Moderna’s new mRNA flu shot just got FDA approval—marking the first time this cutting-edge tech hits the market, designed for adults 50 and up. While past skepticism about mRNA’s flu-fighting potential lingered, doctors like Dr. Parvati Ananthula see it as a powerful tool to prevent severe illness, not necessarily infection. Backed by a massive 40,000-person trial showing nearly 27% fewer flu cases, the vaccine may offer faster adaptation to new strains—a game-changer for high-risk groups. It’s rolling out this fall in the U.S. and already gaining traction abroad.
Listen in comfort: Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn.
Advertise on DNN: advertise@thednn.ai
This is an automated, high-level news summary based on public reporting. Report issues to feedback@thednn.ai.
Podden och tillhörande omslagsbild på den här sidan tillhör
The Daily News Now!. Innehållet i podden är skapat av The Daily News Now! och inte av,
eller tillsammans med, Poddtoppen.
